Guggenheim Downgrades AnaptysBio to Neutral

Guggenheim downgrades AnaptysBio (NASDAQ:ANAB) from Buy to Neutral.

Benzinga · 11/08/2019 15:05

Guggenheim downgrades AnaptysBio (NASDAQ:ANAB) from Buy to Neutral.